Target intelligence / Profile preview

Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2 (ALKBH2)

Target: ALKBH2
Molecular classification: Enzyme, Dioxygenase, Oxidoreductase, Fe(II)/α-ketoglutarate-dependent dioxygenase family

Overview

Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2 (ALKBH2) is a human enzyme responsible for the direct reversal repair of alkylated DNA bases—specifically, it catalyzes the oxidative demethylation of lesions such as N1-methyladenine and N3-methylcytosine, and higher order etheno adducts including 1,N6-ethenoadenine, 3,N4-ethenocytosine, and 1,N2-ethenoguanine. ALKBH2 uses molecular oxygen, Fe(II), and alpha-ketoglutarate as cofactors to restore undamaged DNA bases, maintaining genomic stability especially during alkylation stress. It preferentially acts on double-stranded DNA, deploying key histidine and aspartic acid residues to coordinate iron and facilitate oxygen activation for oxidative repair. ALKBH2 is highly conserved, and dysfunction or deficiency can predispose to mutagenic processes and cancer. While it is a member of a larger family of AlkB homologs, ALKBH2 is distinguished by its substrate specificity and duplex DNA preference.

Other names: ALKBH2AlkB homolog 2AlkB (when referring generically, but should be distinguished from other family members and bacterial AlkB)alpha-ketoglutarate-dependent dioxygenase alkB homolog 2

Mechanism of action

Inhibition: Small molecules could inhibit ALKBH2's dioxygenase activity, potentially impacting DNA repair in cancer therapies - Enhancement: Activators or upregulation could theoretically enhance DNA repair in genotoxic stress contexts

Biological functions

DNA repair (oxidative demethylation of alkylated bases, direct reversal mechanism)Maintenance of genomic integrity under alkylation stressAlkylation lesion recognition and base flipping in duplex DNARNA demethylation (less prominent than DNA repair)

Disease associations

Cancer (deficiency or altered function can affect genome stability and mutagenesis)Other diseases related to genomic instability (no direct role in inflammation, neurodegeneration, cardiovascular disease or infection has been established in the literature cited)

Safety considerations

Potential risk of mutagenesis and genomic instability if ALKBH2 is inhibited (risk for cancer progression, secondary malignancies)Therapeutic challenge: targeting ubiquitous DNA repair may cause off-target cytotoxicity

Interacting drugs

No specific clinical drugs directly targeting ALKBH2 are reported in the cited literature; research chemicals and inhibitors targeting DNA repair pathways may interact.

Biomarkers

No specific biomarkers for patient selection or efficacy monitoring in clinical use were cited; mutations, expression levels, or activity of ALKBH2 may be used in research settings as markers of DNA repair capacity

Beyond the preview

Go deeper on Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2 (ALKBH2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2 (ALKBH2).

Explore the full profile